This website is intended for U.S. Healthcare Professionals.
REVLIMID is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.
Recommended dose adjustments1
Recommended starting dose adjustments for patients with renal impairment.
Capsules shown are not actual size.
Dose modification is recommended to manage Grade 3 or 4 hematologic events thought to be related to therapy with REVLIMID.1
Thrombocytopenia
NEUTROPENIA
For non-hematologic Grade 3 or 4 toxicities judged to be related to REVLIMID, hold treatment and restart treatment at the next lower dose level when toxicity has resolved to ≤Grade 2 at the physician’s discretion.
Permanently discontinue REVLIMID for angioedema, anaphylaxis, Grade 4 rash, skin exfoliation, bullae, or any other severe dermatologic reactions.
